SCHEMBL1008045

SCHEMBL1008045

O=C(O)CCCCCCCc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 1.00
RXFP1 Q9HBX9 1/20 1.00
HDAC1 Q13547 2/20 0.83
HDAC2 Q92769 2/20 0.83
HDAC3 O15379 1/20 0.83
MAPK1 P28482 1/20 0.83
ADRA1A P35348 1/20 0.83
HDAC4 P56524 1/20 0.83
SLC6A3 Q01959 1/20 0.83
SMN1; SMN2 Q16637 1/20 0.83
HDAC7 Q8WUI4 1/20 0.83
HDAC10 Q969S8 1/20 0.83
HDAC11 Q96DB2 1/20 0.83
HDAC8 Q9BY41 1/20 0.83
HDAC6 Q9UBN7 1/20 0.83
HDAC9 Q9UKV0 1/20 0.83
HDAC5 Q9UQL6 1/20 0.83
KEAP1 Q14145 1/20 0.68
ALOX5 P09917 1/20 0.67
KDM4A O75164 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2552651 1.00 MAPT (1.00) MAPTRXFP1HDAC1HDAC2HDAC3
Phenylheptanoic Acid SCHEMBL535246 1.00 MAPT (1.00) MAPTRXFP1HDAC1HDAC2HDAC3
SCHEMBL5955839 1.00 MAPT (1.00) MAPTRXFP1HDAC1HDAC2HDAC3
SCHEMBL503837 1.00 MAPT (1.00) MAPTRXFP1HDAC1HDAC2HDAC3
SCHEMBL2554345 1.00 MAPT (1.00) MAPTRXFP1HDAC1HDAC2HDAC3
SCHEMBL770290 1.00 MAPT (1.00) MAPTRXFP1HDAC1HDAC2HDAC3
SCHEMBL2555645 1.00 MAPT (1.00) MAPTRXFP1HDAC1HDAC2HDAC3
SCHEMBL1008757 1.00 MAPT (1.00) MAPTRXFP1HDAC1HDAC2HDAC3
SCHEMBL2553009 1.00 MAPT (1.00) MAPTRXFP1HDAC1HDAC2HDAC3
SCHEMBL2551105 1.00 MAPT (1.00) MAPTRXFP1HDAC1HDAC2HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116060124-B Oil-soluble organic metal salt composition and preparation method and application thereof 中国石油化工股份有限公司 2024-06-28 CN claimed
CN-116060125-B Cobalt-molybdenum bimetal organic salt composition and preparation method and application thereof 中国石油化工股份有限公司 2024-05-31 CN claimed
CN-116060130-B Organic molybdenum salt composition and preparation method and application thereof 中国石油化工股份有限公司 2024-05-31 CN claimed
CN-116060130-A Organic molybdenum salt composition and preparation method and application thereof 中国石油化工股份有限公司 2023-05-05 CN claimed
CN-116060124-A Oil-soluble organic metal salt composition and preparation method and application thereof 中国石油化工股份有限公司 2023-05-05 CN claimed
CN-116060125-A Cobalt-molybdenum bimetal organic salt composition and preparation method and application thereof 中国石油化工股份有限公司 2023-05-05 CN claimed
CN-110256632-B Preparation method of chromium-free polyolefin resin with high branching degree 中韩(武汉)石油化工有限公司 2022-05-24 CN claimed
CN-110585278-A Health-care vinasse applying mud and preparation method thereof 安徽省金裕皖酒业有限公司 2019-12-20 CN claimed
CN-110300791-A Quantum dot dispersion, self-luminous photosensitive resin composition, color filter, and image display device 东友精细化工有限公司 2019-10-01 CN claimed
WO-2011124227-A1 BIOCIDAL ACID-ADJUSTED POLYMER WITH POLYPROPYLENE VESTERGAARD FRANDSEN SA (CH) 2011-10-13 WO claimed
WO-2011124228-A1 A BIOCIDAL POLYOLEFIN YARN WITH 3-12 FILAMENTS VESTERGAARD FRANDSEN SA (CH) 2011-10-13 WO claimed
WO-1999029640-A2 COMPOSITIONS AND METHODS FOR MODULATING THE ACTIVITY OF FIBROBLAST GROWTH FACTOR EISAI CO., LTD. (JP) 1999-06-17 WO claimed
US-20250332124-A1 MITOFUSIN ACTIVATORS HAVING AN ENDOCYCLIC-BONDED CARBONYL GROUP AND METHODS FOR USE THEREOF DORN II GERALD W (US) 2025-10-30 US disclosed
US-12396968-B2 Mitofusin activators having an endocyclic-bonded carbonyl group and methods for use thereof DORN II GERALD W (US) 2025-08-26 US disclosed
US-20250170156-A1 TOLL-LIKE RECEPTOR LIGANDS INIMMUNE CORP (US) 2025-05-29 US disclosed
CN-117377651-B Cationic lipid with side chain containing functional groups and application thereof 厦门赛诺邦格生物科技股份有限公司 2025-04-01 CN disclosed
WO-1985004805-A1 PROCESS FOR WASTE NITROGEN REMOVAL BRUSILOW SAUL W (US) 1985-11-07 WO disclosed
US-4457942-A Process for waste nitrogen removal UCYCLYD PHARMA, INC. 1984-07-03 US disclosed
US-4323513-A Production of methyl esters and ethylene glycol esters from reaction of carbon monoxide and hydrogen in presence of ruthenium catalyst UNION CARBIDE CORPORATION (US) 1982-04-06 US disclosed
US-4212939-A Substrate solution for carboxylic ester hydrolase determination THE UNIVERSITY OF ALABAMA (US) 1980-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12396968-B2 Mitofusin activators having an endocyclic-bonded carbonyl group and methods for use thereof MFN2, CYCS, CYC1 MAPT 3784/4885RXFP1 2516/4885HDAC1 703/4885
US-20250170156-A1 TOLL-LIKE RECEPTOR LIGANDS TLR1, TLR4, TLR6 MAPT 1596/4885RXFP1 933/4885HDAC1 983/4885
US-20250332124-A1 MITOFUSIN ACTIVATORS HAVING AN ENDOCYCLIC-BONDED CARBONYL GROUP AND METHODS FOR USE THEREOF MFN2, CYCS, CYC1 MAPT 3745/4885RXFP1 2555/4885HDAC1 698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.